Carole Devaux is a scientist actively working in the field of infectious diseases and immunotherapy. She is currently the Head of the Infection and Immunotherapy Research Group at the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH), where she also serves as Deputy Head of Quality and Safety.

With over 20 years of research experience, she led the HIV Clinical and Translational Research Group from 2014 to 2024, contributing to the development of new therapeutic strategies. Previously, she held key positions at CRP-Santé in Luxembourg, INSERM in France, and the University of Pittsburgh in the USA, after earning a PhD in Biological and Medical Engineering from Henri Poincaré University.

Dr. Carole Devaux demonstrates a significant commitment to infectious disease research and public health. Her influence is evident in her role as President of the 'Comité de surveillance du SIDA' in Luxembourg since 2017, showcasing her direct impact on national health policy. She actively contributes to the scientific community as a board member of the Luxembourg Society For Microbiology and as a council member of the European Society for Translational Antiviral Research. She is currently a member of several international scientific committees and a consultant for the European Drug Agency as a Drug-Related Infectious Diseases expert, for the European Centre for Disease Prevention and Control as an HIV surveillance expert, and for the Ministry of Health Luxembourg as an expert on the national plan for antimicrobial resistance research.

Her research activities have resulted in over 124 scientific publications.

Through her commitment to translational research, Carole Devaux works to bridge the gap between laboratory science and clinical applications, developing new therapies based on innate immunity modulation for the treatment of infectious diseases and cancer.

Dr. Carole Devaux